Cancer risk with tocilizumab/sarilumab, abatacept, and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study.

Rasmus WestermannRené Lindholm CordtzKirsten DuchLene MellemkjaerMerete Lund HetlandBergur MagnussenLene Dreyer

Published in: Rheumatology (Oxford, England) (2024)

Treatment with tocilizumab/sarilumab, abatacept, or rituximab in RA patients was not associated with increased risks of cancer compared with TNFi-treated and with bDMARD-naïve RA patients in a real-world setting.

Keyphrases

rheumatoid arthritis
end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
rheumatoid arthritis patients
prognostic factors
diffuse large b cell lymphoma
disease activity
patient reported outcomes
climate change
smoking cessation
childhood cancer